Correct Option (A)
Hybridoma technology is a method for producing large quantities of identical antibodies, known as monoclonal antibodies. This process involves fusing antibody-producing B lymphocytes (plasma cells) from an immunized animal with myeloma cells (cancerous B cells) that can proliferate indefinitely. The resulting hybrid cells, called hybridomas, possess the ability to both produce specific antibodies and multiply continuously in cell culture, thereby enabling the commercial-scale production of highly specific monoclonal antibodies for various applications in diagnostics, therapeutics, and research.
Incorrect Options:
Option B: Interferons are a group of signaling proteins produced and released by host cells in response to the presence of several pathogens, such as viruses, bacteria, parasites, and tumor cells. While interferons have biotechnological applications, their commercial production typically involves recombinant DNA technology, not hybridoma technology.
Option C: Antibodies, in general, are proteins produced by the immune system to identify and neutralize foreign objects like bacteria and viruses. While hybridoma technology produces a specific type of antibody (monoclonal antibodies), the term "antibodies" is too broad. Polyclonal antibodies, for instance, are a mixture of antibodies produced by different B cell clones and can be obtained directly from immunized animals without hybridoma technology.
Option D: Alcohol, specifically ethanol, is primarily produced through the fermentation of sugars by microorganisms like yeast. This process is distinct from biotechnological methods involving cell fusion, such as hybridoma technology.